3 results
Primary objective of the study is•To investigate the change of Urinary Albumin-to-Creatinine ratio (UCAR) after 90 days treatment Secondary objectives of the study are•To assess safety and tolerability of these doses by assessing the effects on…
Part A - CX-2009 Monotherapy: Every 21-Day Dosing RegimenThe primary objective of Part A is to determine the safety profile of CX-2009, the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the dose-limiting toxicities(DLTs) of CX-…
1. To compare the following imaging technologies to the current practice of histology of pelvic lymph node dissection: a. PSMAGa68 PET b. Nano MR Lymphography and an enhanced arterial map (Nano MRL / EAM) to locate the position of the lymph nodes2.…